Article

Mini glaucoma shunt reimbursement increases under new classification

Optonol announced in a prepared statement that its proprietary mini glaucoma shunt (Ex-PRESS) will be paid under a new ambulatory payment classification (APC) beginning Jan. 1, 2009.

Neve Ilan, Israel-Optonol announced in a prepared statement that its proprietary mini glaucoma shunt (Ex-PRESS) will be paid under a new ambulatory payment classification (APC) beginning Jan. 1, 2009.

The shunt now is assigned to APC 673 (Level IV Anterior Segment Eye Procedures), according to the published Centers for Medicare and Medicaid Services (CMS) 2009 Hospital Outpatient Prospective System Final Rule. In the hospital outpatient setting, the national average reimbursement for the shunt increased from $1476.16 to $2705.35. In the Ambulatory Surgery Center (ASC) setting, the payment increased from $949 to $1652.98.

“We are pleased that CMS reconsidered the reimbursement level to make the procedure available to Medicare beneficiaries,” said Patrick King, president of Optonol. “This will allow glaucoma surgeons access to the . . . mini glaucoma shunt in both the hospital outpatient setting and the ASC.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
© 2025 MJH Life Sciences

All rights reserved.